Preoperative Intravenous Omega 3 Fatty Acids Administration in Elderly Patients Undergoing Hip Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by Nizam's Institute of Medical Sciences University, India.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Nizam's Institute of Medical Sciences University, India
ClinicalTrials.gov Identifier:
NCT00890123
First received: April 28, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
  Purpose

The perioperative administration of n-3 fatty acids has been shown to lead to favorable effects on outcome in patients with severe surgical interventions by lowering the magnitude of inflammatory response and by modulating the immune response. No study with preoperative administration of IV omega 3 fatty acids as a part of total parenteral nutrition (TPN) or monotherapy with it to demonstrate its effects on inflammatory and immune response has been conducted. So, this study has been planned to judge the inflammatory response of preoperative monotherapy with IV omega 3 fatty acids in elderly patients undergoing hip surgery considering the hyperinflammation associated with this type of surgery in elderly patients.


Condition Intervention Phase
Hip Surgery
Dietary Supplement: Omegaven-IV FO
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Preoperative Intravenous Omega 3 Fatty Acids Administration in Elderly Patients Undergoing Hip Surgery: A Prospective, Randomized, Open-Label, Comparative Clinical Trial

Resource links provided by NLM:


Further study details as provided by Nizam's Institute of Medical Sciences University, India:

Primary Outcome Measures:
  • IL-6, 8, 10, HS-CRP levels [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Infectious complications [ Time Frame: 5 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: April 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
Dietary Supplement: Omegaven-IV FO
Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
No Intervention: 2
Will not receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days.

  Eligibility

Ages Eligible for Study:   60 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Elderly male or female patients undergoing hip surgeries
  2. Age > 60 years
  3. The patients who give written informed consent

Exclusion Criteria:

  1. Refusal to participate in the study
  2. Allergy to any of the constituents of nutritional products
  3. HIV positive patients, patients with primary diagnosis of hypertriglyceridemia, patients on long term steroid therapy and cyclooxygenase inhibitors (more than 3 months)
  4. Severe cardiac disease, hepatic disorders (total bilirubin > 1.5 times the upper limit of normal), psychiatric disorders likely to affect compliance, severe hemorrhagic disorders, stroke, embolism
  5. Uncontrolled severe renal failure (Serum creatinine > 2 mg/dL) without dialysis/hemofiltration
  6. Participation in any other clinical trial within the last 2 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Dr R Gopinath, NIMS-Hyderabad-India
ClinicalTrials.gov Identifier: NCT00890123     History of Changes
Other Study ID Numbers: Omegaven Hip Surgery
Study First Received: April 28, 2009
Last Updated: April 28, 2009
Health Authority: India: Institutional Review Board

Keywords provided by Nizam's Institute of Medical Sciences University, India:
IVOmega 3 FA
Inflammation
Hip Surgery
Inflammatory status
Infectious complications

ClinicalTrials.gov processed this record on August 26, 2014